Hua Medicine confirms patient enrollment for study of diabetes drug
Category: #health  By Mateen Dalal  Date: 2019-03-03
  • share
  • Twitter
  • Facebook
  • LinkedIn

Hua Medicine confirms patient enrollment for study of diabetes drug

Shanghai-based drug development firm Hua Medicine, which focuses on developing global first-in-class oral drug for treating Type 2 diabetes, has recently announced that it has completed patient enrollment for a Phase III monotherapy trial of dorzagliatin (HMS5552). The company is expecting to release topline results from the study in the fourth quarter of 2019.

CEO of Hua Medicine, Dr. Li Chen, was quoted saying that this milestone takes the company one step closer to bringing dorzagliatin to the Chinese market, which consists of 120 million Type 2 diabetics.  The novel, first-in-class drug would be a 3rd generation T2D drug, since it holds the potential to stop the progression of T2D, something which existing drugs have not been able to achieve, he said.

Dr. Chen added that the protocol follows the company’s Phase II study design, which provided strong efficacy and safety data along with promising disease modifying effects. Hua Medicine informed that the Phase III monotherapy registration trial would target patients who are drug naïve, which will position dorzagliatin as a first-line therapy. The trial is a placebo-controlled, double-blind study with patients being randomized 2:1 for receiving either placebo or dorzagliatin.

The clinical study would apparently evaluate the safety and efficacy of dorzagliatin with 24-week long double-blinded treatment plus 28 weeks of open-label treatment and follow-up. The study will be conducted at 40 clinical sites all over China, the company mentioned.

For the record, first-in-class glucokinase activator (GKA) dorzagliatin, is a drug designed for controlling diabetes’ progressive degenerative nature by restoring glucose homeostasis in Type 2 diabetics. Hua Medicine reportedly in-licensed dorzagliatin’s global rights from Roche.

Essentially, dorzagliatin has the potential to repair the impaired glucose homeostasis state in Type 2 diabetics by tackling the defect of the glucose sensor function of glucokinase, Hua Medicine stated. This can make the drug a first line standard of care therapy for treating patients with Type 2 Diabetes, or even as a cornerstone therapy to be applied in combination with existing anti-diabetes drugs which are approved.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Ather Energy raises $250 million to stay ahead in competition
Ather Energy raises $250 million to stay ahead in competition
By Mateen Dalal

Electric scooter producer Ather Energy has reportedly secured $250 million in a new funding round. As per reports, the investment round is in its early stages. The company’s goal is to obtain $200 million to $250 million to compete in the EV...

Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
By Mateen Dalal

Mojocare, a wellness and health startup has reportedly raised USD 20.6 million in a Series A round of funding which was led by B Capital Group and saw participation from existing investors including Sequoia India’s Surge, Better Capital, and Ch...

Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
By Mateen Dalal

Bangalore-based Exponent Energy has reportedly secured USD 13 million in a Series A funding round which was spearheaded by Lightspeed Venture Partners. The round also saw participation from existing investors such as 3one4 Capital, YourNest VC, and A...